RNS Number:0268P
Genetix Group PLC
27 August 2003

                 Genetix Appoints Chief Operating Officer

New Milton UK, 27 August 2003 - Genetix Group plc (LSE: GTX), the genomics and
proteomics technology group, today announces the appointment of Trevor Bell, 46,
as Chief Operating Officer with effect from 15 September 2003.

With a background in international marketing and brand management gained in a
variety of blue chip consumer goods companies including Procter & Gamble and
Jacobs Suchard, Mr Bell has spent much of the last 14 years operating in senior
General Management positions in Europe, North America and Asia Pacific.

These have included Remy Cointreau SA, where he was Managing Director Northern
Europe, and in the Healthcare sector with Scholl plc, where, as Board Director
responsible for Global Commercial Operations, he achieved significant sales and
profit growth prior to the agreed merger of the company in June 1998 with Seton
Healthcare plc.

Mr Bell has extensive experience of the key North American market, which
accounts for over 50% of Genetix's sales, having been resident in the United
States in his most recent corporate position as President of Schwinn Fitness,
the manufacturer and marketer of fitness equipment, based in Boulder, Colorado.
Since leaving Schwinn, Mr Bell has been advising a number of companies in the
USA, Asia Pacific and Europe.

Mark Reid, CEO of Genetix, said: "We are pleased to welcome Trevor to the Board.
His broad business experience and international marketing expertise will be of
particular benefit to Genetix and his appointment marks a further strengthening
of our executive team."

With reference to paragraphs 16.4 and 6.F.2 (b)-(g). of the UKLA's Listing Rules
there are no other disclosures required other than in respect of paragraph 6.F.2
(d), where after leaving the company in October 2000 Schwinn/GT UK Sales was put
into administrative receivership in March 2001 as part of internal
reorganisation.


Enquiries:

Genetix Group plc
Mark Reid, Chief Executive Officer         Tel:  +44 (0) 1425 624600
Gary Corsi, Finance Director

Financial Dynamics
Jonathan Birt / Sarah MacLeod              Tel:  +44 (0) 7831 3113

Notes to Editors

Genetix Group plc is based in New Milton, Hampshire, UK.  It develops,
manufactures and markets high-throughput equipment and related items used for
research into human and plant genomics, proteomics and cell biology. The Company
currently supplies equipment to more than 150 customers worldwide in the
pharmaceutical, agricultural and food industries including GlaxoSmithKline,
AstraZeneca, Novartis, Celera Genomics, Millennium Pharmaceuticals and the Max
Planck Institutes.  In addition, the Group has made a significant contribution
to the Human Genome Project by supplying equipment to seven of the leading eight
laboratories involved in the consortium.  Genetix acquired the Genpak group in
October 2000 before floating successfully on the London Stock Exchange in
November 2000.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCILFLSTIIRFIV